Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has said it is to pay a settlement of $35 million to Watson Pharmaceuticals, ending patent litigation related to the antidepressant Wellbutrin XL.
Subscribe to our email newsletter
<p>The original litigation related to Andrx Corporation which Watson acquired for $1.9 billion in 2006. <br /><br />In 2005, Andrx Corporation filed a patent infringement lawsuit in a US District Court against GlaxoSmithKline alleging that its Wellbutrin XL extended-release tablets in 150mg infringed Andrx's patent. <br /><br />Andrx has granted GlaxoSmithKline a royalty-bearing license to the patent. Other terms of the settlement and license were not disclosed.</p>